

## **Evaluation of deep learning software tool for CT based lung nodule growth assessment**

**Poster No.:** C-3685  
**Congress:** ECR 2019  
**Type:** Scientific Exhibit  
**Authors:** J. Murchison, G. Ritchie, D. Senyszak, E. J. R. Van Beek; Edinburgh/UK  
**Keywords:** Artificial Intelligence, Lung, Oncology, CT, CAD, CT-Quantitative, Computer Applications-Detection, diagnosis, Segmentation, Cancer  
**DOI:** 10.26044/ecr2019/C-3685

Any information contained in this pdf file is automatically generated from digital material submitted to EPOS by third parties in the form of scientific presentations. References to any names, marks, products, or services of third parties or hypertext links to third-party sites or information are provided solely as a convenience to you and do not in any way constitute or imply ECR's endorsement, sponsorship or recommendation of the third party, information, product or service. ECR is not responsible for the content of these pages and does not make any representations regarding the content or accuracy of material in this file.

As per copyright regulations, any unauthorised use of the material or parts thereof as well as commercial reproduction or multiple distribution by any traditional or electronically based reproduction/publication method is strictly prohibited.

You agree to defend, indemnify, and hold ECR harmless from and against any and all claims, damages, costs, and expenses, including attorneys' fees, arising from or related to your use of these pages.

Please note: Links to movies, ppt slideshows and any other multimedia files are not available in the pdf version of presentations.

[www.myESR.org](http://www.myESR.org)

## Aims and objectives

Despite lung cancer preventive strategies, lung cancer remains the third highest cause of cancers worldwide [1] with a rising incidence of the disease still being reported [2]. In addition, lung cancer is the commonest cause of cancer related deaths [3] accounting for around 1.7 million deaths globally each year. This high mortality rate is at least in part due to the fact that lung cancer is often diagnosed at an advanced stage of disease. The results of the National Lung Screening Trial (NLST) showed that early detection of lung cancer is possible using low-dose CT in a high-risk population and that this is associated with a decrease in both lung cancer related and overall mortality. This has led to the approval of lung cancer screening in the USA [4]. The benefits of lung cancer screening and early detection of lung cancer are also supported by the findings of the Benelux NELSON trial.

Lung cancer is ideally diagnosed by histopathological confirmation on a tissue sample. However, the diagnostic process usually begins with detection of pulmonary nodules or masses, usually through medical imaging. Pulmonary nodules are very common and most are benign, however benign and malignant nodules can have identical appearances, so all should be flagged up as potential cancers. The biggest challenges when it comes to pulmonary nodule detection on CT are acceptable sensitivity levels and reading times. The importance of high sensitivity for pulmonary nodule detection is underscored by the fact that many failures in lung cancer diagnosis are due to errors of detection rather than interpretation [5,6]. Over the last two decades a substantial number of studies [7,8,9] have evaluated the performance of (sub-specialist) radiologists for the specific task of detecting pulmonary nodules and have shown that there is room for improvement.

In addition, pulmonary nodule guidelines recommend the use of different cut-off levels for nodule size and/or volume and volume doubling time as metrics to assess nodule size and growth [10-16]. Most recently, there seems to be consensus that semi-automated volume assessment gives the most robust assessment for lung nodules and is most helpful for determining growth during follow up. [14-16] Apart from the measurement of size and/or volume, another important parameter to consider is the makeup of pulmonary nodules (solid vs sub-solid), as their malignant potential is significantly different. [17] In spite of both these size/volume and composition management guidelines, many hospitals currently do not have the the tools to perform these measurements in a timely and accurate manner, both due to a lack of software and due to a lack of suitably trained radiologists. Therefore, software aided detection and classification of lung nodules would be a welcome addition to the radiologist's diagnostic arsenal and could facilitate the roll-out of CT lung cancer screening as has been advocated [18].

The objective of this study was to evaluate the clinical performance of a Deep Learning computer assisted diagnosis system (CAD) for growth assessment of lung nodules on CT Chest.

## Methods and materials

Patient population: A total of 349 chest CT examinations from 324 unique subjects were retrospectively selected from the NHS Lothian database. Eligibility of CT scans for each group was determined using information from the radiology reports with cross referencing to the electronic health records as appropriate. Subjects for the first two groups were selected to mimic a lung cancer screening population. Inclusion criteria were subjects between 50-74 years of age, current smokers or those with a smoking history and/or reported to have radiological evidence of pulmonary emphysema were found eligible for the first two groups. Group 1 consists of 181 CT scans which were clinically reported as being free from pulmonary nodules and group 2 consists of 100 CT scans which were reported to have at least 1 and no more than 10 pulmonary nodule(s). Group 3 consists of 25 CT scans which were followed up for the presence of a pulmonary nodule, group 4 consists of the follow-up CT scans of group 3. Finally, group 5 consists of 18 CT scans with part-solid and/or ground-glass nodule(s) described in the original radiology report. Group 5 was intended to increase the overall number of sub-solid nodules. Specific exclusion criteria were slice thickness >3mm and the presence of diffuse pulmonary disease in the radiology report and/or the CT images, with widespread abnormalities such as interstitial lung disease, which is very likely to lead to significant symptoms and therefore didn't correspond with an asymptomatic screening subject.

Data acquisition: Patients were scanned with Aquilion (n=330), Aquilion-CX (n=2), and Aquilion ONE (n=1) CT scanners from Canon Medical Systems (formerly Toshiba Medical Systems), Otawara, Japan and LightSpeed (n=2), LightSpeed Plus (n=2) CT scanners from General Electric Medical Systems, Waukesha, United States. Average tube peak potential was 120 kVp, (median: 120 kVp, range: 120-140 kVp). Average tube current was 243 mAs (median: 232 mAs, range: 80-491 mAs) and the average CTDIvol was 14.0 mGy (median: 14.8 mGy; range: 2.9-29.7). Data were reconstructed at a mean slice thickness of 1.0 mm (median: 1.0mm, range 1.0-2.5mm). The following reconstruction kernels were used for CT scans from Canon Medical Systems FC03 (n=120), FC07 (n=99), FC08 (n=4), FC10 (n=3), FC12 (n=7), FC30 (n=1), FC51 (n=99) and LUNG (n=3), STANDARD (n=1) for CT scans from GE Medical Systems. All CT scans were reconstructed using filtered back-projection.

CAD software: The CAD software evaluated in this study was Veye Chest version 2.0 (Aidence B.V., Amsterdam, the Netherlands).

Image annotation: A two-phase process was developed for the asynchronous interpretation by a panel of three thoracic radiologists with at least 9 years experience in reading Chest CT scans, JM, GR and EB, expert readers 1, 2 and 3, respectively. Prior to the start of the study each reader received training on the annotation tasks and how to

use the annotation tool. A comprehensive set of written instructions was available during the entire annotation process.

In summary, the initial "blinded" phase required readers 1 and 2 to independently perform a free search on all CT scans on a radiology reporting workstation. In half of the CT scans, which were selected at random, the detection results of CAD were made available. The study design ensured that each CT scan was reviewed twice, once by each reader, once by one reader with the results of CAD (AIDED) and once by the other reader without (UNAIDED). Readers were asked to identify all lesions which they considered to be a pulmonary nodule without clear benign morphological characteristics (i.e. calcified nodules). They could mark a pulmonary nodule by adding a manual annotation or classify a CAD prompt as either a true positive or false positive. They were required to register all nodules that were present on CT scans from both groups 3 and 4, where possible. Finally, the readers also classified all false positive prompts in three different groups: micro-nodules (largest axial diameter <3mm), masses (largest axial diameter >30mm), benign nodules (benign calcification pattern or clear benign perifissural appearance), non-nodules (any finding that could not be classified in any of the other sub-groups). Subsequently, non-nodules were further classified as: pleural plaque, scar tissue, atelectasis, fibrosis, fissure thickening, pleural fluid, pleural thickening, intrapulmonary vessels, consolidations, outside of lung tissue, or other (free format). After completing all the readings on the workstations the readers subsequently reviewed their own previously identified nodules on a tablet (iPad Pro). The reader was asked to determine the composition (solid or sub-solid) of the nodule and subsequently segment the nodule on every slice by delineating the border using a stylus (Apple Pencil). After the blinded phase was completed the results from readers 1 and 2 were evaluated for the presence of any discrepancies. Discrepancies were defined as a difference between the results in terms of: location (3D dice coefficient of 0); composition; segmentation (3D dice coefficient < -1 standard deviation of the mean 3D dice coefficient) and nodule registration. The second "unblinded" phase required reader 3 to adjudicate all discrepancies from the blinded phase without the results of CAD, free search was not allowed. The review was performed using the same materials used in the blinded phase. Reader 3 created a third independent reading for each nodule that had a discrepancy for at least one characteristic.

*Reference standard:* The reference standard for nodule registration was created using CT scans from groups 3 and 4, subsequently growth rate was determined as the relative volume difference between a nodule visible on a CT scan from group 3 and on a study from group 4.

*Data analysis:* When looking at nodules visible on sequential scans nodule registration from CAD was scored as either a true positive-pair (TP-pair), if the detected registration was included in the nodule registration reference standard, or otherwise as a false

positive-pair (FP-pair). The mean discrepancy between growth percentages determined by readers and CAD alone was calculated.

Images for this section:

Groups	Number of unique subjects	Number CT scans	Total number of nodules between	
			≥3 and <5mm	≥5mm / ≥80mm <sup>3</sup> and <30mm
1	178	178	19	71
2	95	95	34	198
3	23	23	0	68
4		23	6	36
5	18	18	2	36
<b>TOTAL</b>	<b>314</b>	<b>337</b>	<b>61</b>	<b>409</b>

Table 1. Number of unique subjects, scans and nodules in each of the 5 groups.

Table 1: Table 1: Demographics of the groups included in the study.

© Queen's Medical Research Institute, Clinical Research Imaging Centre - Edinburgh/UK



Fig. 1: Figure 1: Nodule detection by the software, confirmed by thoracic radiologist.

© Queen's Medical Research Institute, Clinical Research Imaging Centre - Edinburgh/UK

## Results

A total of 337 CT scans from 314 subjects (173 women, 164 men) with a total of 470 pulmonary nodules (largest axial diameter between #3mm and #30mm) were included in this study. The mean age of all the subjects was  $63 \pm 7$  years (range 32-88 years). Details regarding the number of CT scans and nodules per group are described in table 1. The mean largest axial diameter of all nodules in groups 1 to 5 was  $7.68 \pm 3.50$  mm (range: 3.42 - 28.45 mm) and the mean volume was  $198 \pm 333$  mm<sup>3</sup> (range: 21 - 2797 mm<sup>3</sup>).

The total number of nodules in group 3 and 4 was 68 and 42, respectively. The total number of nodule-pairs in groups 3 and 4 was 23. The sensitivity for detecting nodule pairs of CAD alone was 100.0% and the average number of FP-pairs was 0.0. The mean growth percentage discrepancy of readers and CAD alone was 1.30 (95% CI: 1.02, 2.21) and 1.35 (95% CI: 1.01, 4.99), respectively.



Images for this section:

Groups	Number of unique subjects	Number CT scans	Total number of nodules between	
			≥3 and <5mm	≥5mm / ≥80mm <sup>3</sup> and <30mm
1	178	178	19	71
2	95	95	34	198
3	23	23	0	68
4		23	6	36
5	18	18	2	36
<b>TOTAL</b>	<b>314</b>	<b>337</b>	<b>61</b>	<b>409</b>

Table 1. Number of unique subjects, scans and nodules in each of the 5 groups.

**Table 1:** Table 1: Demographics of the groups included in the study.

© Queen's Medical Research Institute, Clinical Research Imaging Centre - Edinburgh/UK



# Nodule Analysis Report

Patient ID 203087  
Accession Number 0412714186246023  
Study Date 02-01-2001




Prior Accession Number 7171162179189200  
Prior Study Date 02-01-2000  
Time between 366 days

Nodule: 1  
Slice: 141  
Composition: Solid




Growth: 138%  
VDT: 292 days  
VDT CI: (264, 325)

Current study: 02-01-2001

	Diameter (mm)	Volume (mm <sup>3</sup> )	Volume CI
Current	9x6 (8)	233	(223, 244)
Prior	6x4 (5)	98	(90, 106)



Prior study: 02-01-2000 - Slice 146



**Fig. 2:** Figure 2: Nodule segmentation and volume measurement, with follow-up study demonstrating volume doubling time capabilities.

© Aidence BV, Amsterdam, the Netherlands

## Conclusion

The mean growth percentage of lung nodule pairs was similar between readers and by stand-alone CAD. These results show that the tool has the potential to assist radiologists at pulmonary nodule management, although visual verification of the segmentation is still advised at present.

## Personal information

Address for correspondence:

Professor John T Murchison, Consultant Radiologist, Royal Infirmary of Edinburgh, Little France Crescent, Edinburgh, UK. Email: john.murchison@luht.scot.nhs.uk

Declaration of interest:


This study was funded by NHS England via the SBRI Phase 1 grant for earlier detection and treatment of cancer. Aidence BV received the grant from SBRI and commissioned the University of Edinburgh and Royal Infirmary of Edinburgh to perform the study. Prof. J.T. Murchison, Dr. G. Ritchie and Prof J.R. van Beek received a consulting fee for reading and annotating the studies.

Prof. Van Beek is a member of the Advisory Board of Aidence.

Prof. Murchison, Dr. Ritchie and Mr. Senyszak declare no interest.

## References

1. International Agency for Research on Cancer (IARC). GLOBOCAN 2018.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
3. International Agency for Research on Cancer (IARC). GLOBOCAN Cancer Fact Sheets: Lung Cancer. International Agency for Research on Cancer (IARC); 2017,



<http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf>. Accessed 2018.

4. Centers for Medicare & Medicaid Services (CMS).(2015) Decision memo for screening for lung cancer with low dose computed tomography (LDCT) (CAG-00439N). CMS website. [www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274](http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274). Accessed February 19, 2017

5. Kakinuma R, Ohmatsu H, Kaneko M et al. (1999) Detection failures in spiral CT screening for lung cancer: analysis of CT findings. *Radiology* 212: 61-6

6. White CS, Romney BM, Mason AC, Austin JH, Miller BH, Protopapas Z (1996) Primary carcinoma of the lung overlooked at CT: analysis of findings in 14 patients. *Radiology* 199:109-15

7. Kakinuma R, Ashizawa K, Kobayashi T et al (2012) Comparison of sensitivity of lung nodule detection between radiologists and technologists on low-dose CT lung cancer screening images. *Br J Radiol* 85:e603-8

8 Roos JE, Paik D, Olsen D et al. (2010) Computer-aided detection (CAD) of lung nodules in CT scans: radiologist performance and reading time with incremental CAD assistance. *Eur Radiol* 20: 549-57

9. Nair A, Gartland N, Barton B et al (2016) Comparing the performance of trained radiographers against experienced radiologists in the UK lung cancer screening (UKLS) trial. *Br J Radiol* 89:20160301

10. Church TR, Black WC, Aberle D, et al. (2013) National Lung Screening Trial. *New Engl J Med* 368:1980-91.

11. Callister MEJ, Baldwin DR, Akram AR, et al.(2015) The BTS guideline for the investigation and management of pulmonary nodules. *Thorax* 2015;70 (suppl 2).

12. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT imaging: From the Fleischner Society 2017. *Radiology* 284:228-43.

13. McKee BJ, Regis SM, McKee AB, Flacke S, Wald C. (2015) Performance of ACR lung-RADS in a clinical CT lung screening program. *J Am Coll Radiol* 12:273-6.

14. Bankier AA, MacMahon H, Goo JM, Rubin GD, Schaefer-Prokop CM, Naidich DP. (2017) Recommendations for measuring pulmonary nodules at CT: A statement from the Fleischner Society. *Radiology* 285:584-600.
15. Deveraj A, van Ginneken B, Nair A, Baldwin D. (2017) Use of volumetry for lung nodule management: theory and practice. *Radiology* 284:630-44.
16. Heuvelmans MA, Walter JE, Vliegenthart R, et al. (2018) Disagreement of diameter and volume measurements for pulmonary nodule size estimation in CT lung cancer screening. *Thorax* 73:779-81.
17. Oudkerk M, Deveraj A, Vliegenthart R, et al. (2017). European position statement on lung cancer screening. *Lancet Oncol* 18:e754-66.
18. Naidich DP, Bankier AA, MacMahon H, et al. (2013) Recommendations for the management of subsolid pulmonary nodules detected at CT: A statement from the Fleischner Society. *Radiology* 266:304-17.